VANI Key Statistics, Chart & Performance
The current stock price of VANI is 1.48 USD. In the past month the price increased by 8.03%. In the past year, price increased by 20.33%.
VANI Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to VANI. When comparing the yearly performance of all stocks, VANI turns out to be only a medium performer in the overall market: it outperformed 59.16% of all stocks.
VANI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to VANI. The financial health of VANI is average, but there are quite some concerns on its profitability.
VANI Financial Highlights
Over the last trailing twelve months VANI reported a non-GAAP Earnings per Share(EPS) of -0.45. The EPS decreased by 0% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -103.91% | ||
| ROE | -1988.24% | ||
| Debt/Equity | 0 |
VANI Forecast & Estimates
9 analysts have analysed VANI and the average price target is 5.1 USD. This implies a price increase of 244.59% is expected in the next year compared to the current price of 1.48.
VANI Ownership
About VANI
Company Profile
Vivani Medical, Inc. is a preclinical stage biopharmaceutical company, which engages in the business of developing miniaturized, subdermal implants utilizing proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. The company is headquartered in Alameda, California and currently employs 42 full-time employees. The company went IPO on 2014-12-05. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.
Company Info
VIVANI MEDICAL INC
1350 S. Loop Road
Alameda CALIFORNIA US
Employees: 42
Phone: 14155068462
VIVANI MEDICAL INC / VANI FAQ
Can you describe the business of VIVANI MEDICAL INC?
Vivani Medical, Inc. is a preclinical stage biopharmaceutical company, which engages in the business of developing miniaturized, subdermal implants utilizing proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. The company is headquartered in Alameda, California and currently employs 42 full-time employees. The company went IPO on 2014-12-05. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.
What is the current price of VANI stock?
The current stock price of VANI is 1.48 USD. The price increased by 0.68% in the last trading session.
What is the dividend status of VIVANI MEDICAL INC?
VANI does not pay a dividend.
What is the ChartMill technical and fundamental rating of VANI stock?
VANI has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the sector and industry classification for VIVANI MEDICAL INC?
VIVANI MEDICAL INC (VANI) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
How many employees does VIVANI MEDICAL INC have?
VIVANI MEDICAL INC (VANI) currently has 42 employees.
What is the market capitalization of VANI stock?
VIVANI MEDICAL INC (VANI) has a market capitalization of 107.97M USD. This makes VANI a Micro Cap stock.